The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or inhalation. A nasal COVID-19 vaccine, developed using technology from Washington ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...

The Food and Drug Administration (FDA) recently gave approval for clinical trials in the U.S. of a COVID-19 nasal vaccine ...

The development of an effective HIV vaccine remains an urgent public health need due to the high genetic variability and rapid mutation rates of the virus, which limit the generation of broadly ...

Experts are concerned about the Clade 1 mpox virus that has been spreading quickly in west and central Africa since 2023.

VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

This study examines the impact of geographically limited disasters on health care quality performance scores of Medicare Advantage contracts, finding limited impact on performance scores.